Figure 5

Immunohistochemical analysis of proliferation and apoptotic markers (A) Immunohistochemical staining for PCNA in colon tumors from rats fed control diet or fed with DFMO, Rosuvastatin or the combination of DFMO and Rosuvastatin. (B) quantification of proliferation in response to the treatments in A. A significant difference was observed in proliferative index between combination-treated and control group tumors. (C) A significant decrease was observed in PCNA protein expression between combination-treated and control group tumors. (D) A significant Increase was observed in p21 protein expression in combination-treated tumors compared to control group tumors. (E) Immunohistochemical staining for p21 in colon tumors from rats fed control diet or fed with DFMO, Rosuvastatin or the combination of DFMO and Rosuvastatin. (F) A significant Increase was observed in p21 nuclear expression in combination-treated tumors compared to control group tumors. (G) A significant Increase was observed in wild type p53 protein expression in combination-treated tumors compared to control group tumors. (H) A significant decrease was observed in mutant type p53 protein expression in combination-treated tumors compared to control group tumors. (I) A significant Increase was observed in PARP protein expression in combination-treated tumors compared to control group tumors.